Engrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by Anhedonia September 18, 2024
AAVantgarde Announces First Patient Dosed with AAVB-081 in FIH Phase 1/2 LUCE-1 Study for Retinitis Pigmentosa Related to USH1B September 16, 2024
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update August 12, 2024
Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update August 12, 2024
XyloCor and SmartCella enter into license agreement for use of the Extroducer to administer novel gene therapy XC001 to the heart July 11, 2024
Interius BioTherapeutics Receives HREC Approval and CTN Clearance from the TGA to Commence a Phase 1 Clinical Trial for Its First-in-Class In Vivo CAR Therapeutic for B Cell Malignancies July 9, 2024
